Cancer Research and Treatment

Original Articles

Gastrointestinal cancer

Second-Line Fluoropyrimidine-Based Chemotherapy in Advanced Biliary Tract Cancer: A Meta-analysis Based on Individual Patient-Level Data of Randomized Trials: Jaewon Hyung, Minsu Kang, Ilhwan Kim, Kyu-pyo Kim, Baek-Yeol Ryoo, Jaekyung Cheon, Hyewon Ryu, Ji Sung Lee, Ji-Won Kim, In Sil Choi, Jin Hyun Park, Ghassan K. Abou-Alfa, Jin Won Kim, Changhoon Yoo; Cancer Res Treat. 2025;57(2):519-527. Published online October 17, 2024; DOI: https://doi.org/10.4143/crt.2024.652

Abstract PDF Supplementary Material PubReader ePub

Purpose
While fluoropyrimidine-based chemotherapy regimens are recommended second-line treatment for patients with advanced biliary tract cancer (BTC), there have been no studies comparing different regimens head-to-head.
Materials and Methods
We performed individual patient-level meta-analysis based on data from the intention-to-treat population of the phase 2b NIFTY trial (liposomal irinotecan [nal-IRI] plus fluorouracil and leucovorin [5-FU/LV] vs. 5-FU/LV; NCT03542508) and the phase 2 FIReFOX trial (modified oxaliplatin plus 5-FU/LV [mFOLFOX] vs. modified irinotecan plus 5-FU/LV [mFOLFIRI]; NCT03464968). Pairwise log-rank tests and multivariable analysis using Cox proportional hazards modeling with shared frailty to account for the trial's effect were used to compare overall survival (OS) between regimens.
Results
A total of 277 patients were included. The nal-IRI plus 5-FU/LV group (n=88) showed significantly better OS compared to the mFOLFOX group (n=49, pairwise log-rank, p=0.02), and mFOLFIRI group (n=50, p=0.03). Multivariable analysis showed consistent trends in OS with adjusted hazard ratios of 1.39 (mFOLFOX vs. nal-IRI plus 5-FU/LV: 95% confidence interval [CI], 0.93 to 2.07; p=0.11) and 1.36 (mFOLFIRI vs. nal-IRI plus 5-FU/LV: 95% CI, 0.92 to 2.03; p=0.13), respectively. Compared to the 5-FU/LV group, the mFOLFOX group and the mFOLFIRI group did not show differences in terms of OS (pairwise log-rank p=0.83 and p=0.58, respectively). The nal-IRI plus 5-FU/LV group experienced more frequent diarrhea, while the mFOLFOX group experienced peripheral neuropathy.
Conclusion
Nal-IRI plus 5-FU/LV showed favorable survival outcomes compared to mFOLFOX, mFOLFIRI, or 5-FU/LV. The safety profiles of these regimens should be considered along with efficacy.

Citations

Citations to this article as recorded by

Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trials
Changhoon Yoo, Anna Saborowski, Jaewon Hyung, Patrick Wenzel, Ilhwan Kim, Henning Wege, Kyu-pyo Kim, Gunnar Folprecht, Baek-Yeol Ryoo, Phillip Schütt, Jaekyung Cheon, Thorsten Götze, Hyewon Ryu, Ji Sung Lee, Arndt Vogel
Journal of Hepatology.2025;[Epub] CrossRef

1,305 View
129 Download
1 Crossref

A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10): Keun-Wook Lee, Dae Young Zang, Min-Hee Ryu, Hye Sook Han, Ki Hyang Kim, Mi-Jung Kim, Sung Ae Koh, Sung Sook Lee, Dong-Hoe Koo, Yoon Ho Ko, Byeong Seok Sohn, Jin Won Kim, Jin Hyun Park, Byung-Ho Nam, In Sil Choi; Cancer Res Treat. 2023;55(4):1250-1260. Published online May 25, 2023; DOI: https://doi.org/10.4143/crt.2023.333

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study evaluated whether combination therapy is more effective than monotherapy in elderly patients with metastatic or recurrent gastric cancer (MRGC) as first-line chemotherapy.
Materials and Methods
Elderly (≥ 70 years) chemo-naïve patients with MRGC were allocated to receive either combination therapy (group A: 5-fluorouracil [5-FU]/oxaliplatin, capecitabine/oxaliplatin, capecitabine/cisplatin, or S-1/cisplatin) or monotherapy (group B: 5-FU, capecitabine, or S-1). In group A, starting doses were 80% of standard doses, and they could be escalated to 100% at the discretion of the investigator. Primary endpoint was to confirm superior overall survival (OS) of combination therapy vs. monotherapy.
Results
After 111 of the planned 238 patients were randomized, enrollment was terminated due to poor accrual. In the full-analysis population (group A [n=53] and group B [n=51]), median OS of combination therapy vs. monotherapy was 11.5 vs. 7.5 months (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.56 to 1.30; p=0.231). Median progression-free survival (PFS) was 5.6 vs. 3.7 months (HR, 0.53; 95% CI, 0.34 to 0.83; p=0.005). In subgroup analyses, patients aged 70-74 years tended to have superior OS with combination therapy (15.9 vs. 7.2 months, p=0.056). Treatment-related adverse events (TRAEs) occurred more frequently in group A vs. group B. However, among severe TRAEs (≥ grade 3), there were no TRAEs with a frequency difference of > 5%.
Conclusion
Combination therapy was associated with numerically improved OS, although statistically insignificant, and a significant PFS benefit compared with monotherapy. Although combination therapy showed more frequent TRAEs, there was no difference in the frequency of severe TRAEs.

Citations

Citations to this article as recorded by

A prognostic nomogram to predict the cancer-specific survival of patients with initially diagnosed metastatic gastric cancer: a validation study in a Chinese cohort
Ziming Zhao, Erxun Dai, Bao Jin, Ping Deng, Zulihaer Salehebieke, Bin Han, Rongfan Wu, Zhaowu Yu, Jun Ren
Clinical and Translational Oncology.2024; 27(1): 135. CrossRef

4,215 View
305 Download
1 Web of Science
1 Crossref

Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients: Seung-Hoon Beom, Dong-Wan Kim, Sung Hoon Sim, Bhumsuk Keam, Jin Hyun Park, Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Dae Seog Heo; Cancer Res Treat. 2016;48(1):88-97. Published online March 3, 2015; DOI: https://doi.org/10.4143/crt.2014.201

Abstract PDF PubReader ePub

Purpose
Interstitial lung disease (ILD) is a serious adverse effect of gefitinib. We examined the incidence and clinical characteristics of drug-induced ILD in Korean non-small cell lung carcinoma patients treated with gefitinib. Materials and Methods A retrospective cohort study was performed in non-small cell lung cancer (NSCLC) patients who started gefitinib treatment at Seoul National University Hospital from January 2002 through December 2011. Patients who developed new abnormal radiologic findings with respiratory symptoms after gefitinib treatment were defined as having possible adverse pulmonary reactions. The patients’ medical records were reviewed independently by investigators to identify the causes of pulmonary toxicities. Results Among the 1,114 patients evaluated, 128 patients (11.5%) developed pulmonary adverse reactions after taking gefitinib. An infectious complication occurred in 98 patients (8.8%) and 15 patients (1.3%) developed ILD. Nine of the 15 patients (60.0%) with gefitinib-induced ILD experienced a fatal clinical course that met either the Common Terminology Criteria for Adverse Events grade 4 (n=3) or grade 5 (n=6). In the multivariate analysis, a lower serum albumin level (≤ 3.0 g/dL) at baseline was significantly associated with the development of gefitinib-induced ILD (odds ratio, 3.91; 95% confidence interval, 1.20 to 12.71). Conclusion The incidence of gefitinib-induced ILD in Korean NSCLC patients was similar to that reported worldwide, but lower than values reported for Japanese population. ILD was usually a lifethreatening adverse effect of gefitinib, and the development of ILD was significantly associated with a lower baseline serum albumin level.

Citations

Citations to this article as recorded by

Incidence and risk of drug-induced interstitial lung disease associated with anti-neoplastic drugs
Il-Hyung Hwang, Seung Hyeun Lee, Hankil Lee
Expert Opinion on Drug Safety.2025; : 1. CrossRef
Risk factors for interstitial lung disease in patients with non-small cell lung cancer with epidermal growth factor receptor-tyrosine kinase inhibitors: A systematic review and meta-analysis
Yosuke Fukuda, Yoshitaka Uchida, Koichi Ando, Ryo Manabe, Akihiko Tanaka, Hironori Sagara
Respiratory Investigation.2024; 62(3): 481. CrossRef
Valsartan prevents gefitinib-induced lung inflammation, oxidative stress, and alteration of plasma metabolites in rats
Wael A. Alanazi, Hussain N. Alhamami, Ali A. Alshamrani, Faleh Alqahtani, Abdulrahman Alshammari, Khalid Alhazzani, Mohammed Alswayyed
Saudi Journal of Biological Sciences.2023; 30(2): 103522. CrossRef
Characteristics and risk of interstitial lung disease in dermatomyositis and polymyositis: a retrospective cohort study in Japan
Qingqing Hu, Kuan-Chih Huang, Choo Hua Goh, Yumi Tsuchiya, Yanfang Liu, Hong Qiu
Scientific Reports.2023;[Epub] CrossRef
Sensorineural hearing loss induced by gefitinib: A CARE-compliant case report and literature reviews
Bao-chen Zhu, Wen-hua Yang, Mao Huang, Jin-gui Wang, Yan Liang, Zhen-zhen Lei, Sha-sha Zhang, Ying Wang, Xiao-di Sun, Ying Gong, Chun-miao Xue, Guo-dong Hua
Medicine.2023; 102(45): e36010. CrossRef
Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism
Alessio Basolo, Antonio Matrone, Rossella Elisei, Ferruccio Santini
Seminars in Cancer Biology.2022; 79: 197. CrossRef
Pulmonary toxicities of molecular targeted antineoplastic agents: a single-center 10-year experience
Min-Young Lee, Seug Yun Yoon, Kyoung Ha Kim, Namsu Lee, Ha Youn Kim, Jung Hwa Hwang, Jong-Ho Won
The Korean Journal of Internal Medicine.2021; 36(3): 689. CrossRef
Management and Prognosis of Interstitial Lung Disease With Lung Cancer (ILD-LC): A Real-World Cohort From Three Medical Centers in China
Xie Xiaohong, Wang Liqiang, Li Na, Lin Xinqing, Qin Yinyin, Liu Ming, Ouyang Ming, Han Qian, Luo Qun, Li Shiyue, Li Chunyan, Wang Xiaoqian, Yang Shuanying, Huang Wei, Liu Mei, Wang Ping, Zhou Chengzhi
Frontiers in Molecular Biosciences.2021;[Epub] CrossRef
Osimertinib for Japanese patients with T790M‐positive advanced non‐small‐cell lung cancer: A pooled subgroup analysis
Tomonori Hirashima, Miyako Satouchi, Toyoaki Hida, Makoto Nishio, Terufumi Kato, Hiroshi Sakai, Fumio Imamura, Katsuyuki Kiura, Isamu Okamoto, Kazuo Kasahara, Hirohiko Uchida, Sarah L. Vowler, Tetsuya Mitsudomi
Cancer Science.2019; 110(9): 2884. CrossRef
Ethnic differences in idiopathic pulmonary fibrosis: The Japanese perspective
Shigeki Saito, Joseph A. Lasky, Koichi Hagiwara, Yasuhiro Kondoh
Respiratory Investigation.2018; 56(5): 375. CrossRef
Personalized chemotherapy of lung cancer: What the radiologist should know
G.R. Ferretti, E. Reymond, A. Delouche, L. Sakhri, A. Jankowski, D. Moro-Sibilot, S. Lantuejoul, A.C. Toffart
Diagnostic and Interventional Imaging.2016; 97(3): 287. CrossRef
Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas
Rashmi R. Shah
Drug Safety.2016; 39(11): 1073. CrossRef
Combination Therapy of Gefitinib and Korean Herbal Medicines Could be a Beneficial Option for Patients with Non-Small-Cell Lung Cancer
Namhun Lee, Kangwook Lee, Yoon-sik Kim, Chang-Gue Son, Jung-Hyo Cho, Hwa-Seung Yoo, Jonghoon Lee, Juyoung Ryu
Journal of Pharmacopuncture.2016; 19(3): 259. CrossRef
Imagerie du suivi post-thérapeutique des traitements personnalisés systémiques du cancer bronchique
G. Ferretti, E. Reymond, J. Cohen, A. Jankowski, M. Giaj-Levra, A.C. Toffart, D. Moro-Sibilot
Revue des Maladies Respiratoires Actualités.2016; 8(5): 325. CrossRef

15,315 View
134 Download
15 Web of Science
14 Crossref

Case Report

A Unique Case of Erdheim-Chester Disease with Axial Skeleton, Lymph Node, and Bone Marrow Involvement: Jin Lim, Ki Hwan Kim, Koung Jin Suh, Kyung Ah Yoh, Jin Young Moon, Ji Eun Kim, Eun Youn Roh, In Sil Choi, Jin-Soo Kim, Jin Hyun Park; Cancer Res Treat. 2016;48(1):415-421. Published online February 26, 2015; DOI: https://doi.org/10.4143/crt.2014.160

Abstract PDF PubReader ePub

Erdheim-Chester disease is a rare non-Langerhans–cell histiocytosis with bone and organ involvement. A 76-year-old man presented with low back pain and a history of visits for exertional dyspnea. We diagnosed him with anemia of chronic disease, cytopenia related to chronic illness, chronic renal failure due to hypertension, and hypothyroidism. However, we could not determine a definite cause or explanation for the cytopenia. Multiple osteosclerotic axial skeleton lesions and axillary lymph node enlargement were detected by computed tomography. Bone marrow biopsy revealed histiocytic infiltration, which was CD68-positive and CD1a-negative. This report describes an unusual presentation of Erdheim-Chester disease involving the bone marrow, axial skeleton, and lymph nodes.

Citations

Citations to this article as recorded by

Erdheim Chester Disease Mimicking Lymphoma: A Case Report
Philipp Moritz Wunschel, Wolfgang Voss, Marc Keberle
RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren.2022; 194(03): 310. CrossRef
Myelopathy Secondary to Isolated Thoracic Spine Involvement Mimicking Metastasis in Erdheim–Chester Disease
Rajesh Rajavelu, Ajoy P. Shetty, Rishi M. Kanna, S Rajasekaran
Indian Spine Journal.2021; 4(1): 133. CrossRef
Diagnosing a Patient with Erdheim-Chester Disease during the COVID-19 Pandemic
Georgia Kaiafa, Dimitrios Pilalas, Triantafyllia Koletsa, Stylianos Daios, Georgios Arsos, Adam Hatzidakis, Adonis Protopapas, Kostas Stamatopoulos, Christos Savopoulos
Medicina.2021; 57(10): 1001. CrossRef
Case of Erdheim–Chester presenting with xanthelasma-like eruption and osteolytic bone lesions: A case report
Evelyn Alarcon Chinchilla, Marie-Pascale Gourde, Karine Turcotte, Steve Mathieu, Mohamed Amin-Hashem
SAGE Open Medical Case Reports.2019;[Epub] CrossRef
Erdheim-Chester Disease Involving Lymph Nodes and Liver Clinically Mimicking Lymphoma: A Case Report
Yeoun Eun Sung, Yoon Seo Lee, Jieun Lee, Kyo Young Lee
Journal of Pathology and Translational Medicine.2018; 52(3): 183. CrossRef
Resolved heart tamponade and controlled exophthalmos, facial pain and diabetes insipidus due to Erdheim-Chester disease
Jaume Monmany, Esther Granell, Laura López, Pere Domingo
BMJ Case Reports.2018; : bcr-2018-225224. CrossRef
18F-FDG PET/CT in Erdheim–Chester Disease: Imaging Findings and Potential BRAF Mutation Biomarker
Jason R. Young, Geoffrey B. Johnson, Robert C. Murphy, Ronald S. Go, Stephen M. Broski
Journal of Nuclear Medicine.2018; 59(5): 774. CrossRef
Erdheim-Chester Disease with Emperipolesis: A Unique Case Involving the Heart
Pengcheng Zhu, Naping Li, Lu Yu, Mariajose Navia Miranda, Guoping Wang, Yaqi Duan
Cancer Research and Treatment.2017; 49(2): 553. CrossRef

18,931 View
97 Download
9 Web of Science
8 Crossref

Original Articles

Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Bhumsuk Keam, Dong-Wan Kim, Jin Hyun Park, Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Doo Hyun Chung, Dae Seog Heo; Cancer Res Treat. 2014;46(4):323-330. Published online July 14, 2014; DOI: https://doi.org/10.4143/crt.2013.120

Abstract PDF PubReader ePub

Purpose
The aim of this study was to develop a pragmatic nomogram for prediction of progressionfree survival (PFS) for the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in EGFR mutant non-small cell lung cancer (NSCLC).
Materials and Methods
A total of 306 recurred or metastatic NSCLC patients with EGFR mutation, who received EGFR TKIs, were enrolled in this study. We developed the nomogram, using a Cox proportional hazard regression model for PFS.
Results
The median PFS was 11.2 months. Response rate to EGFR TKI was 71.9%. Multivariate Cox model identified disease status, performance status, chemotherapy line, response to EGFR TKI, and bone metastasis as independent prognostic factors, and the nomogram for PFS was developed, based on these covariates. The concordance index for a nomogram was 0.708, and the calibration was also good.
Conclusion
We developed a nomogram, based on clinical characteristics, for prediction of the PFS to EGFR TKI in NSCLC patients with EGFR mutation.

Citations

Citations to this article as recorded by

Real-world prognostic factors for first-line EGFR-TKI efficacy in advanced NSCLC patients harboring EGFR 21 L858R mutation
Yan’e Liu, Lu Chen, Xin Zhu, Hua Zhang, Baoshan Cao
Global Medical Genetics.2025; 12(2): 100051. CrossRef
To establish a prognostic model of epidermal growth factor receptor mutated non-small cell lung cancer patients based on Least Absolute Shrinkage and Selection Operator regression
Bowen Li, Xiaopeng Zhang
European Journal of Cancer Prevention.2024; 33(4): 368. CrossRef
A predictive model of computed tomography and clinical features of EGFR gene mutation in lung adenocarcinoma
Youjian Yao, Nengde Zhang, Caiwei Lu, Lianhua Liu, Yu Fu, Mei Gui
Science Progress.2024;[Epub] CrossRef
Hallmark guided identification and characterization of a novel immune-relevant signature for prognostication of recurrence in stage I–III lung adenocarcinoma
Yongqiang Zhang, Zhao Yang, Yuqin Tang, Chengbin Guo, Danni Lin, Linling Cheng, Xun Hu, Kang Zhang, Gen Li
Genes & Diseases.2023; 10(4): 1657. CrossRef
Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI
John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Chiao-En Wu
Cancers.2022; 14(4): 977. CrossRef
Establishment of prognostic nomograms for predicting the progression free survival of EGFR‐sensitizing mutation, advanced lung cancer patients treated with EGFR‐TKIs
Xinyang Du, Hua Bai, Zhijie Wang, Jianchun Daun, Zheng Liu, Jiachen Xu, Geyun Chang, Yixiang Zhu, Jie Wang
Thoracic Cancer.2022; 13(9): 1289. CrossRef
Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data
Lourdes Gutiérrez, Ana Royuela, Enric Carcereny, Rafael López-Castro, Delvys Rodríguez-Abreu, Bartomeu Massuti, José Luis González-Larriba, Rosario García-Campelo, Joaquim Bosch-Barrera, María Guirado, Carlos Camps, Manuel Dómine, Reyes Bernabé, Joaquín C
BMC Cancer.2021;[Epub] CrossRef
The Ki-67 Proliferation Index-Related Nomogram to Predict the Response of First-Line Tyrosine Kinase Inhibitors or Chemotherapy in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor-Mutant Status
Weiguo Gu, Mingbin Hu, Linlin Xu, Yuanhui Ren, Jinhong Mei, Weijia Wang, Chunliang Wang
Frontiers in Medicine.2021;[Epub] CrossRef
A nomogram to predict outcomes of lung cancer patients after pneumonectomy based on 47 indicators
Bo Cheng, Cong Wang, Bing Zou, Di Huang, Jinming Yu, Yufeng Cheng, Xue Meng
Cancer Medicine.2020; 9(4): 1430. CrossRef
Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer
Chan-Young Ock, Shin-Hye Yoo, Bhumsuk Keam, Miso Kim, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Doo Hyun Chung, Dae Seog Heo
The Korean Journal of Internal Medicine.2019; 34(5): 1116. CrossRef
The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy
Ji Young Choi, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo, Seong Jin Jo
Cancer Research and Treatment.2019; 51(1): 169. CrossRef
Development and validation of nomograms for predicting survival probability of patients with advanced adenocarcinoma in different EGFR mutation status
Hsi-Chieh Chen, Elise Chia-Hui Tan, Chih-Hsien Liao, Zhong-Zhe Lin, Ming-Chin Yang, Wan-Teck Lim
PLOS ONE.2019; 14(8): e0220730. CrossRef
An inflammation-related nomogram for predicting the survival of patients with non-small cell lung cancer after pulmonary lobectomy
Ying Wang, Xiao Qu, Ngar-Woon Kam, Kai Wang, Hongchang Shen, Qi Liu, Jiajun Du
BMC Cancer.2018;[Epub] CrossRef
Clinical nomograms: Is a picture worth a thousand words?
Kaitlin C. McLoughlin, R. Taylor Ripley
The Journal of Thoracic and Cardiovascular Surgery.2017; 153(2): 470. CrossRef
Prognostic Factors and Scoring Model for Survival in Metastatic Biliary Tract Cancer
Hyung Soon Park, Ji Soo Park, You Jin Chun, Yun Ho Roh, Jieun Moon, Hong Jae Chon, Hye Jin Choi, Joon Seong Park, Dong Ki Lee, Se-Joon Lee, Dong Sup Yoon, Hei-Cheul Jeung
Cancer Research and Treatment.2017; 49(4): 1127. CrossRef
An international epidemiological analysis of young patients with non-small cell lung cancer (AduJov-CLICaP)
Luis Corrales-Rodríguez, Oscar Arrieta, Luis Mas, Renata Báez-Saldaña, Omar Castillo-Fernández, Normand Blais, Claudio Martín, Melissa Juárez, Priyanka Khanna, Allan Ramos-Esquivel, Ludwing Bacon, Leonardo Rojas, Beatriz Wills, George Oblitas, María Angel
Lung Cancer.2017; 113: 30. CrossRef
The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors
Hyungjin Kim, Chang Min Park, Bhumsuk Keam, Sang Joon Park, Miso Kim, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo, Jin Mo Goo, Fan Yang
PLOS ONE.2017; 12(11): e0187500. CrossRef
Nomograms for predicting progression and efficacy of post-operation radiotherapy in IIIA-pN2 non-small cell lung cancer patients
Baozhong Zhang, Zhiyong Yuan, Lujun Zhao, Qingsong Pang, Ping Wang
Oncotarget.2017; 8(23): 37208. CrossRef
A Nomogram to Predict Recurrence and Survival of High-Risk Patients Undergoing Sublobar Resection for Lung Cancer: An Analysis of a Multicenter Prospective Study (ACOSOG Z4032)
Michael S. Kent, Sumithra J. Mandrekar, Rodney Landreneau, Francis Nichols, Nathan R. Foster, Thomas A. DiPetrillo, Bryan Meyers, Dwight E. Heron, David R. Jones, Angelina D. Tan, Sandra Starnes, Joe B. Putnam, Hiran C. Fernando
The Annals of Thoracic Surgery.2016; 102(1): 239. CrossRef
Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitors
Yu-Mu Chen, Chien-Hao Lai, Kun-Ming Rau, Cheng-Hua Huang, Huang-Chih Chang, Tung-Ying Chao, Chia-Cheng Tseng, Wen-Feng Fang, Yung-Che Chen, Yu-Hsiu Chung, Yi-Hsi Wang, Mao-Chang Su, Kuo-Tung Huang, Shih-Feng Liu, Hung-Chen Chen, Ya-Chun Chang, Yu-Ping Cha
Lung Cancer.2016; 98: 99. CrossRef
Prognostic Scoring Index for Patients with Metastatic Pancreatic Adenocarcinoma
Hyung Soon Park, Hye Sun Lee, Ji Soo Park, Joon Seong Park, Dong Ki Lee, Se-Joon Lee, Dong Sup Yoon, Min Goo Lee, Hei-Cheul Jeung
Cancer Research and Treatment.2016; 48(4): 1253. CrossRef

21,661 View
130 Download
25 Web of Science
21 Crossref

How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution: Bhumsuk Keam, Dong-Wan Kim, Jin Hyun Park, Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Doo Hyun Chung, Dae Seog Heo; Cancer Res Treat. 2013;45(3):178-185. Published online September 30, 2013; DOI: https://doi.org/10.4143/crt.2013.45.3.178

Abstract PDF PubReader ePub

PURPOSE
Gefitinib was introduced in 2002 for treatment of non-small cell lung cancer (NSCLC); however, it is not clear whether its use in daily practice has changed the outcome of patients. The purpose of this study is to evaluate the question of how molecular understanding regarding gefitinib and epidermal growth factor receptor (EGFR) mutation affect the prescribing patterns and clinical outcomes of treatment with gefitinib in NSCLC, in a real practical field.
MATERIALS AND METHODS
We conducted a retrospective analysis of the consecutive database of NSCLC patients who were treated with gefitinib at Seoul National University Hospital between January 2002 and December 2011. Prescribing patterns and clinical outcomes were analyzed by year.
RESULTS
A total of 1,115 NSCLC patients, who received gefitinib at recurred or metastatic setting, were included in this study. Proportion of patients receiving gefitinib, for the first line, showed a gradual increase, from 5.2% in 2002-2003 to 30.6% in 2010-2011. Proportion of patients who underwent EGFR mutation testing showed a rapid increase, from 0.6% in 2004-2005 to 73.5% in 2010-2011. The response rate also showed a gradual increase, from 17.2% in 2002-2003 to 57.1% in 2010-2011 (p<0.001). The median progression-free survival of gefitinib was increased with statistical significance from 2.8 months in 2002-2003 to 9.1 months in 2010-2011 (p<0.001).
CONCLUSION
We demonstrated that molecular understanding and practical use of EGFR mutation testing have resulted in a change in the prescription patterns of gefitinib. Use of an enrichment strategy can lead to improvement in the efficacy of gefitinib in real practice.

Citations

Citations to this article as recorded by

Utilisation and Determinants of Epidermal Growth Factor Receptor Mutation Testing in Patients with Non-small Cell Lung Cancer in Routine Clinical Practice: A Global Systematic Review
Aye Myat Thi, Sandar Tin Tin, Mark McKeage, J. Mark Elwood
Targeted Oncology.2020; 15(3): 279. CrossRef
The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy
Ji Young Choi, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo, Seong Jin Jo
Cancer Research and Treatment.2019; 51(1): 169. CrossRef
EGFR Mutation Testing of non-squamous NSCLC: Impact and Uptake during Implementation of Testing Guidelines in a Population-Based Registry Cohort from Northern New Zealand
Mark McKeage, Mark Elwood, Sandar Tin Tin, Prashannata Khwaounjoo, Phyu Aye, Angie Li, Karen Sheath, Phillip Shepherd, George Laking, Nicola Kingston, Christopher Lewis, Donald Love
Targeted Oncology.2017; 12(5): 663. CrossRef
EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study
Baohui Han, Sergei Tjulandin, Koichi Hagiwara, Nicola Normanno, Laksmi Wulandari, Konstantin Laktionov, Achmad Hudoyo, Yong He, Yi-Ping Zhang, Meng-Zhao Wang, Chien Ying Liu, Marianne Ratcliffe, Rose McCormack, Martin Reck
Lung Cancer.2017; 113: 37. CrossRef
The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors
Hyungjin Kim, Chang Min Park, Bhumsuk Keam, Sang Joon Park, Miso Kim, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo, Jin Mo Goo, Fan Yang
PLOS ONE.2017; 12(11): e0187500. CrossRef
Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients
Seung-Hoon Beom, Dong-Wan Kim, Sung Hoon Sim, Bhumsuk Keam, Jin Hyun Park, Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Dae Seog Heo
Cancer Research and Treatment.2016; 48(1): 88. CrossRef
Evolution of targeted therapies in cancer: opportunities and challenges in the clinic
Sam Santhosh, Prasanna Kumar, Vedam Ramprasad, Amitabha Chaudhuri
Future Oncology.2015; 11(2): 279. CrossRef
Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non–Small-Cell Lung Cancer with Activating EGFR Mutation
Bhumsuk Keam, Soo Jin Lee, Tae Min Kim, Jin Chul Paeng, Se-Hoon Lee, Dong-Wan Kim, Yoon Kyung Jeon, Doo Hyun Chung, Keon Wook Kang, June-Key Chung, Dae Seog Heo
Journal of Thoracic Oncology.2015; 10(8): 1189. CrossRef
The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer
Sung Hoon Sim, Bhumsuk Keam, Dong-Wan Kim, Tae Min Kim, Se-Hoon Lee, Doo Hyun Chung, Dae Seog Heo
Journal of Cancer Research and Clinical Oncology.2014; 140(12): 2135. CrossRef

12,122 View
70 Download
9 Crossref

Case Report

A Case of Desmoplastic Small Round Cell Tumor Diagnosed in a Young Female Patient: Ji-Won Kim, Jin Hyun Park, Hyeon Jin Cho, Ji-Hyun Kwon, Youngil Koh, Su-Jung Kim, Se Hyung Kim, Se-Hoon Lee, Seock-Ah Im, Yong-Tae Kim, Woo Ho Kim; Cancer Res Treat. 2009;41(4):233-236. Published online December 31, 2009; DOI: https://doi.org/10.4143/crt.2009.41.4.233

Abstract PDF PubReader ePub

Desmoplastic small round cell tumor is a very rare malignancy. We report the case of a 26-year-old woman who suffered from dyspepsia and abdominal pain for 2 months. We performed an endoscopic biopsy of the duodenal mass and diagnosed her disease as desmoplastic small round cell tumor using immunohistochemical staining, fluorescence in situ hybridization, and reverse transcriptase polymerase chain reaction. Because the mass invaded the pancreas and superior mesenteric vein as well as duodenum and the disease was disseminated to liver and peritoneum, she received palliative chemotherapy using vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide. The maximal response to chemotherapy was stable disease. The patient expired 9 months after diagnosis.

Citations

Citations to this article as recorded by

Intra-Abdominal Desmoplastic Small Round Cell Tumor: Current Treatment Options and Perspectives
Guixia Wei, Xinyao Shu, Yuwen Zhou, Xia Liu, Xiaorong Chen, Meng Qiu
Frontiers in Oncology.2021;[Epub] CrossRef
A Case Report of Abdominal Desmoplastic Small Round Cell Tumor in a Young Tunisian Woman
Karim Nacef, Mohamed Ali Chaouch, Rym Bouriga, Mohamed Ben Khalifa, Asma Chaouch, Mossab Ghannouchi, Moez Boudokhane
Journal of Gastrointestinal Cancer.2019; 50(3): 568. CrossRef
Primary desmoplastic small-round-cell tumor of the ovary
Ahmed Atef, Khaled Gaballa, Mohammad Zuhdy, Khalid Atallah, Wagdi Elkashef, Shadi Awny, Basma Gadelhak, Basel Refky
Journal of the Egyptian National Cancer Institute.2019;[Epub] CrossRef
Tumor intraabdominal desmoplásico de células pequeñas y redondas
Andrés Alejandro Briseño-Hernández, Deissy Roxana Quezada-López, Lilia Edith Corona-Cobián, Agar Castañeda-Chávez, Alfonso Tonatiuh Duarte-Ojeda, Michel Dassaejv Macías-Amezcua
Cirugía y Cirujanos.2015; 83(3): 243. CrossRef
Intra-abdominal desmoplastic small round cell tumour
Andrés Alejandro Briseño-Hernández, Deissy Roxana Quezada-López, Lilia Edith Corona-Cobián, Agar Castañeda-Chávez, Alfonso Tonatiuh Duarte-Ojeda, Michel Dassaejv Macías-Amezcua
Cirugía y Cirujanos (English Edition).2015; 83(3): 243. CrossRef
Primary desmoplastic small round cell tumor of the duodenum
Qi Liu, Nan Liu, DeXing Chen
European Journal of Medical Research.2014;[Epub] CrossRef
Tumor desmoplásico de células pequeñas y redondas. Diagnóstico y tratamiento
Izaskun Markinez Gordobil, Inmaculada Ruiz, Raúl Jiménez, Eloisa Villarreal, Aintzane Lizarazu, Nerea Borda, Xabier Arteaga, Miguel Ángel Medrano, Esther Guisasola, Adolfo Beguiristain, José María E. Navascués
Gaceta Médica de Bilbao.2012; 109(3): 101. CrossRef
Desmoplastic small round cell tumor of the abdomen: A case report and literature review of therapeutic options
Hafida Benhammane, Leila Chbani, Abdelmalek Ousadden, Ouadii Mouquit, Siham Tizniti, Afaf Riffi Amarti, Nouafal Mellas, Omar El Mesbahi
Health.2012; 04(04): 207. CrossRef
Analysis of Prognostic Factors of Pediatric-Type Sarcomas in Adult Patients
Hee Kyung Ahn, Ji Eun Uhm, Jeeyun Lee, Do Hoon Lim, Sung Wook Seo, Ki-Sun Sung, Su Jin Lee, Duk Joo Lee, Kyung Kee Baek, Won-Seog Kim, Joon Oh Park
Oncology.2011; 80(1-2): 21. CrossRef

11,818 View
62 Download
9 Crossref

First
Prev
Page of 1
Next
Last

Search